International Conferences

Also showing items for International Conference

 
News Articles for International Conferences top ^
CLEVELAND, March 26, 2014 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that the Company will present at the 2014 BIO Asia International Conference to be held at the Grand Hyatt in Tokyo, Japan, from April 8-9, 2014.
Sign-up for Athersys to Present at 2014 BIO Asia International Conference investment picks
ATLANTA, April 14, 2014 (GLOBE NEWSWIRE) -- Ebix, Inc. (Nasdaq:EBIX) , a leading international supplier of On-Demand software and E-commerce services to the insurance and healthcare industries, today announced that A.D.A.M., a business unit of Ebix, Inc., will showcase mobile-compatible e-Learning technology solutions with iSpring Solutions, Inc. during a presentation at the ASTD 2014 International Conference and Exposition on Monday, May 5, 2014, 3:00-4:15 p.m. in Washington, D.C. The Solution Session presentation will encourage participants to learn alongside presenters in creating an innovative solution to bring their training solutions to new heights with mobile-compatible e-Learning programs.
Sign-up for A.D.A.M. and iSpring to Present Mobile e-Learning Technology Solutions at ASTD 2014 International Conference and Exposition investment picks
DURHAM, N.C., May 6, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX) , a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced three presentations on its investigational broad-spectrum antiviral brincidofovir (BCV, CMX001) at the 27 th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.
Sign-up for Chimerix's Brincidofovir (CMX001) Data Accepted for Three Presentations at 27th International Conference on Antiviral Research investment picks
VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP) , a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that the company will present a "study in progress" poster on the FLAGSHIP trial of its lead development candidate, AQX-1125, at the 2014 American Thoracic Society (ATS) International Conference.
Sign-up for Corrected - Aquinox Pharmaceuticals Announces Presentation on FLAGSHIP Study at the 2014 American Thoracic Society International Conference investment picks
VANCOUVER, British Columbia, May 14, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq:AQXP) , a clinical stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today announced that the company will present a "study in progress" poster on the FLAGSHIP trial of its lead development candidate, AQX-1125, at the 2014 American Thoracic Society (ATS) International Conference.
Sign-up for Aquinox Pharmaceuticals Announces Presentation on FLAGSHIP Study at the 2014 American Thoracic Society International Conference investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
International Conferences
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: International Conference  |  Next: International Consolidated